Today: 18 July 2026
RELX share price ticks up in London as buyback churns; traders eye Feb 12 results
23 January 2026
1 min read

RELX share price ticks up in London as buyback churns; traders eye Feb 12 results

LONDON, Jan 23, 2026, 09:02 GMT — Regular session

  • RELX shares inched up 0.2% during early London trading, lingering close to their 52-week low
  • Company revealed a fresh batch of buybacks, building on its January repurchase activity
  • Attention now turns to PMI data due later Friday and RELX’s full-year results set for Feb. 12

RELX shares nudged up 0.24% to 2,932 pence in early London trade on Friday, despite a generally cautious market tone. The FTSE 100 rose 0.23%.

The move is modest, with the stock hovering roughly 1% above its 52-week low. Investors are hungry for any sign of stability—whether through consistent buybacks or the upcoming earnings report just around the corner.

European stocks edged lower, heading for a weekly decline as traders digested fresh tensions tied to Greenland and their implications for tariffs as leverage. PMI data, set for release Friday, could swiftly reshape views on growth and interest rates.

RELX revealed Thursday it acquired 322,640 shares via UBS AG London Branch, paying between 2,910 and 2,993 pence each. The volume-weighted average price — the day’s average cost per share — came in at 2,943.9287 pence.

The day before, the company revealed it had bought back 319,226 shares at an average price of 2,965.5152 pence.

Buybacks are standard practice for RELX, yet their impact shifts when the stock hovers close to a one-year low. These repurchases provide a consistent market bid and hint at confidence in cash flow, though they don’t resolve concerns over valuation by themselves.

UK data offered a softer tone for equities on Friday. Retail sales climbed 0.4% in December compared to November, defying forecasts that predicted a 0.1% drop, according to the Office for National Statistics. “The budget was tough, but people’s worst fears weren’t met,” said Neil Birrell, chief investment officer at Premier Miton. Still, Thomas Pugh, chief economist at RSM UK, pointed to political uncertainty as a risk to confidence. Reuters

RELX, a major player in information and analytics with substantial subscription revenue, is typically seen as a defensive bet during volatile sessions. This tends to provide some shelter on risk-off days, yet it also causes the stock to trail behind when investors pivot toward cyclicals and higher-beta stocks.

That said, much could shift from this point. Should PMI numbers drop steeply or tariff tensions reignite, investors might just as quickly sell off “steady” stocks as they bought them. Buyback activity may provide some support during declines, but it won’t be enough to counter a widespread risk-off move.

RELX’s year-end results for Dec. 31, 2025, will drop on Feb. 12. Investors are keyed in on signals about growth, margins, and capital returns — plus if the company keeps up its buyback program.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • SELLAS Life Sciences Jumps on Phase 3 Trial Hopes; High Valuation Poses Questions
    July 18, 2026, 2:52 AM EDT. SELLAS Life Sciences Group (SLS) gained 70% over the last month and is up 203% year-to-date, fueled by rising expectations about Phase 3 results for galinpepimut-S in acute myeloid leukemia. Shares recently traded at $13.19 with a price-to-book ratio of 24.1x, well above both the peer average of 9.1x and the biotechnology sector average of 2.6x, putting the stock at a rich valuation. The premium reflects investor confidence even as SELLAS remains unprofitable and posts negative return on equity. Final trial data offers a key upcoming catalyst, but significant risks persist due to the binary outcome of clinical studies and the absence of current revenue. Investors are urged to consider these factors in line with their individual risk profiles.
British American Tobacco share price in focus before London open after buyback disclosure
Previous Story

British American Tobacco share price in focus before London open after buyback disclosure

Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week
Next Story

Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week

Go toTop